Both in vitro T cell cytotoxicity assays, as well as in vivo combination treatment regimens, suggest that the upregulation of CD38 leads to an immunosuppressed TME and targeting CD38 together with the blockade of the PD-1 axis leads to improved anti-tumor immune responses. Here, CD38 is linked to neoplasm.